DX
Daxor Corporation
DXR · NASDAQ
$11.45 +1.78% (+$0.20)
1M +17.20%
Market Cap $67.9M
P/E Ratio 7.40x
Div. Yield -
ROE 21.69%
Bulios Fair Price
$6.93
39.5% downside
Current Price
$11.45
Undervalued Fair Value Overvalued
According to Bulios Fair Price, DXR is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
4/9Valuation
86 /100
Cheap P/E 7.40x
PEG 0.00x
EV/EBITDA 7.40x
Growth
100 /100
Growing EPS growth 45.29%
Book val. growth 16.57%
Rev. growth N/A
Profitability
65 /100
Moderate Gross margin 37.49%
FCF margin 120.06%
Net margin 1,821.48%
Quality
85 /100
Excellent ROIC 19.96%
Asset turnover 0.01x
ROE 21.69%
Debt
100 /100
Low Debt/Equity 0.00x
Net debt/EBITDA 0.01x
Int. coverage 575.44x
Stability
16 /100
Unstable Beta 0.26x
Profitable years 5
Rev. volatility 5,758.58%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about DXR
Online
Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Michael Richard Feldschuh
Employees
37
Headquarters
Oak Ridge
Upcoming events
10 MAR
Earnings
Upcoming earnings report